CSV January 31, 2023 through January 31, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM	ASSAY/	*USP37–NF32*	4727	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Blank*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SALICYLATE	*Procedure*							Change acetic acid to: glacial acetic acid
ESCITALOPRAM TABLETS	PERFORMANCE TESTS/*Dissolution <711>/Test 2*	*USP37–NF32*	2852	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 3 of *Buffer*: Change phosphoric to: phosphoric acid
THIOTHIXENE	*Limit of (E)-thiothixene/ Standard preparations*	*USP37–NF32*	4942	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *C*: Change Transfer about 200 mg of thiothixene to: Transfer about 200 mg of Thiothixene
HEXACHLOROPHENE LIQUID SOAP	IDENTIFICATION/*B.*	*USP37–NF32*	3231	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Analysis*: Change *Sample solution* to: *Sample*
POWDERED ECHINACEA ANGUSTIFOLIA	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	5346	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 5: Change USP Powdered *Echinacea purpurea* Extract RS

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: USP Powdered *Echinacea angustifolia* Extract RS
MAPROTILINE HYDROCHLORIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP37–NF32*	3655	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 3 of *Analysis*: Change Determine the labeled amount of maprotiline hydrochloride to: Determine the percentage of the labeled amount of maprotiline hydrochloride
POWDERED ECHINACEA PURPUREA EXTRACT	COMPOSITION	*USP37–NF32*	5371	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 14 of *Analysis* in *Content of Total Phenols*: Change C_S = concentration of the relevant analyte in the corresponding *Standard solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_U = concentration of *Echinacea purpurea* in the *Sample solution* (mg/mL) to: C_S = concentration of the relevant analyte in the corresponding *Standard solution* (mg/mL) C_U = concentration of Powdered *Echinacea purpurea* Extract in the *Sample solution* (mg/mL) AND Line 20 of *Analysis* in *Content of Dodecatetraenoic Acid Isobutylamides*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_U = concentration of *Echinacea purpurea* in the *Sample solution* (mg/mL) to: C_U = concentration of Powdered *Echinacea purpurea* Extract in the *Sample solution* (mg/mL)
DESCRIPTION AND SOLUBILITY	*Lauric Acid*	*USP37–NF32*	1506	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 4: Change emulsifying and/or solubilizing agent; tablet and/or capsule lubricant. to: emulsifying agent; lubricant.
OMEPRAZOLE ORAL SUSPENSION	ASSAY/ *Procedure*	*USP37–NF32*	4067	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2 of *Solution A*: Change with dilute phosphoric acid to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								with dilute sodium hydroxide
POWDERED HOLY BASIL LEAF EXTRACT	COMPOSITION /*Content of Triterpenes*	*USP37–NF32*	5458	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 4 of *Standard solution B*: Change 0.45-?L to: 0.45-?m
ALCOHOL IN DEXTROSE INJECTION	ASSAY/ *Dextrose*	*USP37–NF32*	1637	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 15 of *Analysis*: Change *A* = length of the polarimeter tube (mm) to: *A* = 100 mm divided by the length of the polarimeter tube (mm)
PYRANTEL PAMOATE	ASSAY/ *Procedure*	*USP37–NF32*	4491	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Mobile phase*: Change acetic acid to: glacial acetic acid AND Line 1 of *Column*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								efficiency: Change NLT 8000 theoretical plates to: NLT 8000 theoretical plates for the pyrantel peak
CARBAMAZEPINE EXTENDED-RELEASE TABLETS	ASSAY/*Procedure*	*USP37–NF32*	2123	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2 of *Sample stock solution B*: Change *Standard stock solution* to: *Sample stock solution A*
RIBAVIRIN CAPSULES	PERFORMANCE TESTS/*Dissolution <711>*/*Procedure 1*/*Chromatographic system*	*USP37–NF32*	4562	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Column*: Change 7-µm packing L17 to: 9-µm packing L17
DIPHENHYDRAMINE CITRATE AND	IM PURITIES/*Limit of Ibuprofen*	*USP37–NF32*	2651	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 7 of *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IBUPROFEN TABLETS	*Related Compound C*							R_U = peak area ratio of ibuprofen to valerophenone from the *Sample solution* R_S = peak area ratio of ibuprofen to valerophenone from the *Standard solution* to: R_U = peak area ratio of ibuprofen related compound C to valerophenone from the *Sample solution* R_S = peak area ratio of ibuprofen related compound C to valerophenone from the *Standard solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SULFACETAMIDE SODIUM OPHTHALMIC SOLUTION	ASSAY/ *Procedure*	*USP37–NF32*	4766	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2 of *Sample stock solution*: Change sulfacetamide to: sulfacetamide sodium AND Line 1 of *Sample solution*: Change sulfacetamide to: sulfacetamide sodium
GRISEOFULVIN CAPSULES	PERFORMANCE TESTS/ *Uniformity of Dosage Units <905>*/ *Procedure for content uniformity*	*USP37–NF32*	3196	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 6 of *Analysis*: Change Result = $(A_U/A_S) \times (C_S/C_U) \times P \times 100$ to: Result = $(A_U/A_S) \times (C_S/C_U) \times P \times F \times 100$ AND After *P* in definition list:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VALSARTAN	ADDITIONAL REQUIREMENTS/*USP Reference Standards* <11>	*USP37–NF32*	5115	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Add *F* = conversion factor, 0.001 mg/?g Line 2 of USP Valsartan Related Compound A RS: Change (*R*)-*N*-Valeryl-*N*-([2?-(1*H*-tetrazole-5-yl)biphen-4-yl]methyl)valine. to: *N*-Valeryl-*N*-{[2?-(1*H*-tetrazole-5-yl)biphenyl-4-yl]methyl}-D-valine. AND Line 2 of USP Valsartan Related Compound B RS: Change (*S*)-*N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-Butyryl -*N* -([2?-(1*H* -tetrazole-5-yl)biphen-4-yl]methyl)-valine. to: *N* -Butyryl -*N* -{[2?-(1*H* -tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine. AND Line 2 of USP Valsartan Related Compound C RS: Change (*S*)-*N* -Valeryl -*N*-([2'-(1*H* -tetrazole-5-yl)biphen-4-yl]methyl)-valine benzyl ester. to: *N* -Valeryl -*N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-{[2?-(1*H*-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine benzyl ester.
LAMIVUDINE AND ZIDOVUDINE TABLETS	IMPURITIES/*Organic Impurities*	*USP37–NF32*	3484	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 12 of *Analysis*: Change unidentified impurity to: unspecified impurity AND Line 19 of *Analysis*: Change unidentified impurities to: unspecified impurities
POWDERED ECHINACEA PALLIDA	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	5356	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 5: Change USP Powdered *Echinacea purpurea* Extract RS to: USP Powdered *Echinacea pallida* Extract

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NYSTATIN	DEFINITION	*USP37–NF32*	4035	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	RS Line 6: Change extemporaneous solution to: extemporaneous preparation
HOLY BASIL LEAF	COMPOSITION /*Content of Triterpenes*	*USP37–NF32*	5454	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 4 of *Standard solution B*: Change 0.45-?L to: 0.45-?m
DESCRIPTION AND SOLUBILITY	*Sodium Acetate*	*USP37–NF32*	1525	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 7: Change transfer liquid. to: transfer ligand.
PROGESTERONE VAGINAL SUPPOSITORIES	ASSAY/ *Suppositories in Fatty Acid Base*	*USP37–NF32*	4430	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *System suitability solution*: Change Transfer 2.0 mL of *System suitability stock solution A* and *System suitability stock solution B* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CIPROFLOXACIN EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*First Supplement to USP37–NF32*	6619	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Transfer 2.0 mL of each *System suitability stock solution A* and *System suitability stock solution B* AND Line 2 of *Standard solution A*: Change Mix 5.0 of the solution to: Mix 5.0 mL of the solution Line 1 of *Standard solution*: Change 0.56 mg/mL of USP Ciprofloxacin Hydrochloride RS in *Medium* to: 0.62 mg/mL of USP Ciprofloxacin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Hydrochloride RS in *Medium* AND Line 8 of *Analysis*: Change C_S = concentration of ciprofloxacin in the *Standard solution* (mg/mL) to: C_S = concentration of ciprofloxacin hydrochloride in the *Standard solution* (mg/mL)
AMINOSALICYLATE SODIUM	ASSAY/ *Procedure*	*USP37–NF32*	1745	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 15 of *Analysis*: Change C_U = concentration of aminosalicylate in the *Sample solution* (mg/mL) to: C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U$= concentration of Aminosalicylate Sodium in the *Sample solution* (mg/mL)
QUINIDINE GLUCONATE	DEFINITION	*USP37–NF32*	4512	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 6: Change quinidine sulfate to: quinidine gluconate
CODEINE PHOSPHATE ORAL SOLUTION	ASSAY/ *Procedure*	*USP37–NF32*	2451	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 6 of *Analysis*: Change Result = $(R_U/R_S) \times (C_S/C_U) \times 100$ to: Result = $(R_U/R_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ AND After C_U in definition list: Add M_{r1} = molecular weight of codeine phosphate hemihydrate,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								406.37 M_{r2} = molecular weight of anhydrous codeine phosphate, 397.37
SUFENTANIL CITRATE INJECTION	ASSAY/ *Procedure*	*USP37–NF32*	4759	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 11 of *Analysis*: Change sufentanil to: sufentanil citrate
FOSPHENYTOIN SODIUM INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	3096	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Before USP Fosphenytoin Sodium RS: Add USP Endotoxin RS
TRIACETIN	ASSAY/ *Procedure/Titrimetric system*	*USP37–NF32*	5031	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2: Change (See *Titrimetry <541>, Residual Titrations*.) to: (See *Titrimetry <541>*.) AND Line 1 of *Mode*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLOROTHIAZIDE TABLETS	IMPURITIES/*Organic Impurities*	*USP37–NF32*	3247	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Direct titration to: Residual titration Line 11 of *Analysis*: Change C_U = concentration of the *Sample solution* (?g/mL) to: C_U = nominal concentration of hydrochlorothiazide in the *Sample solution* (?g/mL)
POWDERED ECHINACEA ANGUSTIFOLIA EXTRACT	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	5350	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 5: Change USP Powdered *Echinacea purpurea* Extract RS to: USP Powdered *Echinacea angustifolia* Extract RS
METHADONE HYDROCHLORIDE ORAL	OTHER COMPONENTS	*USP37–NF32*	3744	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 3 of *Alcohol Determination*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SOLUTION								Change gas–liquid chromatographic procedure to: gas chromatographic procedure
POWDERED DECAFFEINATED GREEN TEA EXTRACT	COMPOSITION /*Content of Polyphenols/ Chromatographic system*	*USP37–NF32*	5438	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Column*: Change 4.6-mm 6 25-cm; to: 4.6-mm × 25-cm;
DESCRIPTION AND SOLUBILITY	*Potassium Alginate*	*USP37–NF32*	1520	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 6: Change suspending and/or viscosity agent. to: suspending and/or viscosity-increasing agent.
OXCARBAZEPINE TABLETS	IMPURITIES	*USP37–NF32*	4119	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Row 5 of Column 1 of *Table 1*: Change Methoxydibenzazepine[b] to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Methoxycarbamazepine[b]
ORANGE OIL	ASSAY/*Total Aldehyde Content*	*USP37–NF32*	6091	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Sample*: Change 5 mL of Oil to: 5 mL of Orange Oil, accurately weighed
ALUMINA, MAGNESIA, CALCIUM CARBONATE, AND SIMETHICONE CHEWABLE TABLETS	ASSAY/ *Magnesium Hydroxide*	*USP37–NF32*	1674	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 5 of *Magnesium stock solution*: Change Transfer 2.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 20 ?g/mL of magnesium (Mg) to: Transfer 1.0 mL of this solution to a 100-mL volumetric flask to obtain a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution containing 10 ?g/mL of magnesium (Mg)
PYRANTEL PAMOATE	OTHER COMPONENTS/*Content of Pamoic Acid*	*USP37–NF32*	4491	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Mobile phase*: Change acetic acid to: glacial acetic acid
CHLOROXYLENOL	ASSAY/*Procedure*	*USP37–NF32*	2308	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 12 of *Analysis*: Change C_S = concentration of chloroxylenol in the *Standard solution* (mg/mL) to: C_S = concentration of USP Chloroxylenol RS in the *Standard solution* (mg/mL)
RITONAVIR	IMPURITIES	*USP37–NF32*	4601	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Row 13 of Column 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Table 2: Change 3-Epimer[m] to: 3*R*-Epimer[m] AND Row 16 of Column 1 of *Table 2*: Change 5-Epimer[p] to: 5*R*-Epimer[p] AND Row 17 of Column 1 of *Table 2*: Change Valine urea analog[q] to: Diacyl valine urea[q]
DOXEPIN HYDROCHLORIDE ORAL SOLUTION	ASSAY/ *Procedure*	*USP37–NF32*	2713	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Standard solution*: Change Dilute 4.0 of *Standard stock solution* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Dilute 4.0 mL of *Standard stock solution*
TAMSULOSIN HYDROCHLORIDE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 4*	*USP37–NF32*	4830	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 9 of the second calculation: Change *V* = volume of *Buffer stage medium*, 1000 mL to: *V* = volume of *Buffer stage medium*, 500 mL
GRISEOFULVIN TABLETS	ASSAY/ *Procedure*	*USP37–NF32*	3198	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 13 of *Analysis*: Change *P* = potency of griseofulvin in USP Griseofulvin RS (?g/mL) to: *P* = potency of griseofulvin in USP Griseofulvin RS (?g/mg)
ECHINACEA A	ADDITIONAL R	*USP37–NF32*	5343	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 5: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NGUSTIFOLIA	EQUIREMENTS/*USP Reference Standards <11>*							USP Powdered *Echinacea purpurea* Extract RS to: USP Powdered *Echinacea angustifolia* Extract RS
LINDANE CREAM	ASSAY/*Procedure*/*Chromatographic system*/*Temperatures*	*USP37–NF32*	3561	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	After the *Injection port* subsection: Add a new subsection *Detector*: 250°
POWDERED ECHINACEA PALLIDA EXTRACT	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP37–NF32*	5359	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 5: Change USP Powdered *Echinacea purpurea* Extract RS to: USP Powdered *Echinacea pallida* Extract RS
DESCRIPTION AND SOLUBILITY	*Carmellose*	*USP37–NF32*	1486	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 4: Change Suspending and/or viscosity increasing

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								agent; to: Suspending and/or viscosity-increasing agent;
OLMESARTAN MEDOXOMIL	CHEMICAL INFORMATION	*USP37–NF32*	4057	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 3 of the chemical name: Change methyl ester to: methyl ester; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-{[2?-(1*H*-tetrazol-5-yl)biphenyl-4-yl]methyl}-4-(2-hydroxypropan-2-yl)-2-propyl-1*H*-imidazole-5-carboxylate

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 29

- Page 30
- Page 31
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- …
- Next page Next ›
- Last page Last »